E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment Resistant Major Depression |
|
E.1.1.1 | Medical condition in easily understood language |
Depression is a mental disorder characterized by low mood and/or loss of interest or pleasure in nearly all activities. |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057840 |
E.1.2 | Term | Major depression |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy and dose response of intranasal esketamine compared with placebo in improving depressive symptoms in subjects with TRD |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate sustained response (greater than or equal to 50% reduction from baseline in MADRS total score) with onset by Day 2 through the end of the double-blind phase (Day 15).
2. To investigate the safety and tolerability of intranasal esketamine in TRD subjects.
3. To assess the effect of intranasal esketamine compared to intranasal placebo on depressive symptoms, clinical severity of illness, anxiety symptoms, remission, and response.
4. To evaluate the pharmacokinetics (PK) of intranasal esketamine in subjects with TRD. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patient must meet Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition (DSM-5) diagnostic criteria for Major Depressive Disorder (MDD), without psychotic features, based upon clinical assessment, and confirmed by the Mini International Psychiatric Interview (MINI).
- Patient's major depressive episode and treatment response must be deemed "valid" by remote independent raters
- Patient must have had an inadequate response to at least 2 antidepressants, at least one of which is in the current episode of depression. The ATRQ will be used to assess antidepressant treatment response during the current episode. Prior medication history will be used to determine antidepressant treatment response in prior episode(s)
- Have an Inventory of Depressive Symptoms-Clinician rated, 30-item (IDS-C30) total score >=34 at Screening and predose at Day 1 |
|
E.4 | Principal exclusion criteria |
-Patient has a current diagnosis of bipolar and related disorders, intellectual disability, or cluster b personality disorder (e.g., borderline personality disorder, antisocial personality disorder, histrionic personality disorder, and narcissistic personality disorder)
- Patient has a current or prior diagnosis of a psychotic disorder or MDD with psychosis
- Anatomical or medical conditions that may impede delivery or absorption of study medication (e.g., undergone facial reconstruction, significant structural or functional abnormalities of the nose or upper airway; obstructions or mucosal lesions of the nostrils or nasal passages; undergone sinus surgery in the previous 2 years; signs and symptoms of rhinitis)
- Has an abnormal or deviated nasal septum with any 1 or more of the following symptoms: blockage of 1 or both nostrils, nasal congestion (especially 1-sided), frequent nosebleeds, frequent sinus infections, and at times has facial pain, headaches, and postnasal drip
- Patient meets criteria for substance or alcohol use disorder, except tobacco or caffeine, according to DSM-5 criteria at Screening
- Patient has known allergies, hypersensitivity, intolerance, or contraindication to esketamine/ketamine or its excipients |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline to the 1 week endpoint in Montgomery
Asberg Depression Rating scale (MADRS) total score |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
(Day 1 predose, Day 8 predose) to (Day 8 predose, Day 15) |
|
E.5.2 | Secondary end point(s) |
1. Proportion of patients with sustained response (>=50% reduction from baseline in MADRS total score) with onset by Day 2 through the end of the double-blind phase (Day 15)
2. Proportion of responders (>=50% reduction from baseline in MADRS total score) at each visit
3. Proportion of patients in remission (MADRS <=10) at each visit
4. Change from baseline to the 1-week endpoint in patient-reported depressive symptoms using the 16-item quick inventory of depressive symptoms - self report (QIDS-SR16)
5. Change from baseline to the 1-week endpoint in severity of illness using the Clinical Global Impression Severity (CGI-S) rating scale
6. Change from baseline to the 1-week endpoint in severity of illness using the patient global impression - severity (PGI-S)
7. Change from baseline to the 1-week endpoint in anxiety symptoms, as measured by the generalized anxiety disorder 7 item scale (GAD-7) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Day 2 to Day 15
2. Days 1, 2, 4, 8, 9, 11, 14, 15
3. Days 1, 2, 4, 8, 9, 11, 14, 15
4. Day 1 predose to day 8 predose; and day 8 predose to day 15
5. Day 1 predose to day 8 predose; and day 8 predose to day 15
6. Day 1 predose to day 8 predose; and day 8 predose to day 15
7. Day 1 predose to day 8 predose; and day 8 predose to day 15 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Delayed start double randomization design and 0ptional Open-Label phase |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 8 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 8 |